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Efficacy of RG1-VLP Vaccination against Infections
with Genital and Cutaneous Human Papillomaviruses
Christina Schellenbacher1, Kihyuck Kwak2, Dieter Fink3, Saeed Shafti-Keramat1, Bettina Huber1,
Christoph Jindra1, Helena Faust4, Joakim Dillner5, Richard B.S. Roden2 and Reinhard Kirnbauer1
Licensed human papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self-assembled from major
capsid protein L1, afford type-restricted protection against HPV types 16/18/6/11 (or 16/18 for the bivalent vaccine),
which cause 70% of cervical cancers (CxCas) and 90% of genital warts. However, they do not protect against less
prevalent high-risk (HR) types causing 30% of CxCa, or cutaneous HPV. In contrast, vaccination with the minor
capsid protein L2 induces low-level immunity to type-common epitopes. Chimeric RG1-VLP presenting HPV16 L2
amino acids 17–36 (RG1 epitope) within the DE-surface loop of HPV16 L1 induced cross-neutralizing antisera. We
hypothesized that RG1-VLP vaccination protects against a large spectrum of mucosal and cutaneous HPV
infections in vivo. Immunization with RG1-VLP adjuvanted with human-applicable alum-MPL (aluminum
hydroxide plus 3-O-desacyl-40-monophosphoryl lipid A) induced robust L2 antibodies (ELISA titers 2,500–
12,500), which (cross-)neutralized mucosal HR HPV16/18/45/37/33/52/58/35/39/51/59/68/73/26/69/34/70, low-risk
HPV6/11/32/40, and cutaneous HPV2/27/3/76 (titers 25–1,000) using native virion- or pseudovirion (PsV)-based
assays, and a vigorous cytotoxic T lymphocyte response by enzyme-linked immunospot. In vivo, mice were
efficiently protected against experimental vaginal challenge with mucosal HR PsV types HPV16/18/45/31/33/52/58/
35/39/51/59/68/56/73/26/53/66/34 and low-risk HPV6/43/44. Enduring protection was demonstrated 1 year after
vaccination. RG1-VLP is a promising next-generation vaccine with broad efficacy against all relevant mucosal and
also cutaneous HPV types.
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INTRODUCTION
Human papillomaviruses (HPVs) are species-specific, epithe-
liotropic DNA viruses with over 120 types completely char-
acterized today (Bernard et al., 2010). Infections are
widespread and induce lesions from benign papilloma to
intraepithelial neoplasia to carcinoma, the latter representing
5% (Parkin et al., 2005) of the global cancer burden. Persistent
infection with a subset of mucosal HPVs causes high-grade
intraepithelial neoplasias that eventually progress to invasive
cancer of the cervix (CxCa) and of other anogenital and
oropharyngeal sites. More than 15 high-risk (HR) types are
found in almost all CxCas, causing 250,000 deaths in women
worldwide every year (Munoz et al., 2004; de Sanjose et al.,
2010). Low-risk (LR) mucosal HPVs cause anogenital warts in
30 million patients. Common cutaneous HPVs induce skin
warts with substantial impact on high-prevalence groups such
as children or immunocompromised individuals (van Haalen
et al., 2009; Lally et al., 2011). Moreover, a distinct group of
cutaneous (genus b) types have been implicated as subsidiary
causative factor of nonmelanoma skin cancers, although this
remains controversial for those other than patients with the
rare genodermatosis Epidermodysplasia verruciformis (Karagas
et al., 2006; Bouwes Bavinck et al., 2008). Recombinantly
expressed major capsid protein L1 of papillomaviruses self-
assembles into virus-like particles (L1-VLPs) (Kirnbauer et al.,
1992, 1993; Hagensee et al., 1993; Rose et al., 1993; Suzich
et al., 1995) that have been introduced as prophylactic
vaccines. Both (bivalent Cervarix and quadrivalent Gardasil)
licensed vaccines comprise VLPs of HR HPV16/18, which
cause 70% of cervical disease. One (quadrivalent) vaccine
additionally contains VLPs of LR HPV6/11, causing 90% of
genital warts. Prophylactic vaccination confers enduring yet
predominantly vaccine type–restricted protection mediated by
high-titer neutralizing antibodies. To target HPVs responsible
for the remaining third of CxCas (Munoz et al., 2004), a
nonavalent vaccine including 7 HR types is in clinical trials
(http://clinicaltrials.gov). However, the complexity of such a
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vaccine is unlikely to reduce the already very high costs of
current HPV vaccines, which may impede delivery to the
developing world with the highest CxCa burden. Furthermore,
a vaccination strategy against the many types causing skin
papillomas (warts) has not been established (Handisurya et al.,
2009; Senger et al., 2009). Papillomavirus minor capsid
protein L2–based immunogens represent an alternative
strategy to multivalent L1-VLP vaccines. The amino (N)
terminus of L2 contains highly conserved motifs that are
buried in native virions and become exposed only shortly
during the infectious process. However, immunization with L2
peptides alone can induce low-titer antibodies, which mediate
cross-neutralization (Christensen and Kreider, 1991; Kawana
et al., 1999; Roden et al., 2000; Pastrana et al., 2005) in vitro
and cross-protection in animal models in vivo (Chandrachud
et al., 1995; Gambhira et al., 2007a). An HPV16 L2 peptide
comprising amino acids (aa) 17–36 is a broadly cross-
neutralization B-cell epitope recognized by mAb RG1
(Gambhira et al., 2007b). Owing to its essential role for viral
infectivity and its high conservation within many types, the
RG1 epitope may represent an attractive target to develop a
broad-spectrum HPV vaccine. We have previously introduced
chimeric RG1-VLP as a possible strategy to improve
immunogenicity of the RG1 epitope by its genetic insertion
into the immunogenic DE-surface loop of HPV16 L1
(Slupetzky et al., 2007; Kondo et al., 2008; Schellenbacher
et al., 2009; Caldeira Jdo et al., 2010). Upon expression as a
recombinant fusion protein, assembly into capsids repetitively
displaying RG1 epitopes on the capsid surface (RG1-VLP) is
highly efficient. Vaccination induced high-titer neutralizing
antibodies against HPV16 and improved L2-specific
antibodies. Then, available limited in vitro assays demon-
strated cross-neutralization of mucosal HR HPV18/31/45/52/
58, LR HPV HPV6/11, and a single genus b-type (HPV5)
(Schellenbacher et al., 2009). This study comprehensively
examines RG1-VLP vaccine efficacy to cross-protect against
all relevant mucosal HR HPVs in vivo and in vitro, endurance
of protection (an important issue for L2-based vaccine
development), and induction of cell-mediated immunity.
Vaccine efficacy against natural infection was validated
using authentic virion-based neutralization assays.
RESULTS
We have shown previously that vaccination of rabbits and
mice with recombinant RG1-VLP plus alum-MPL (aluminum
hydroxide plus 3-O-desacyl-40-monophosphoryl lipid A)
adjuvant (Schellenbacher et al., 2009) elicited high-titer
neutralizing antibodies to HPV16 and cross-neutralizing
antibodies to pseudovirion (PsV) of the limited number of
then available mucosal HR HPV18/31/45/52/58, LR HPV6/11,
and cutaneous b HPV5.
RG1-VLP vaccination induces a robust antibody response against
the L2 epitope
To assess the robustness of the humoral immune responses to
RG1-VLP, eight additional rabbits were vaccinated either 4 or
3 times (New Zealand White (NZW) nos. 1–6: 4 50mg and
nos. 7–10: 3 20mg) and sera drawn 2 weeks after the last
boost. Robust antibody responses to L2 (titers of 2,500–
12,500) were detected for both vaccination protocols using
the 16L2 N-terminal peptide (aa 11–200) as ELISA antigen
(Supplementary Material online). Conversely, reactivity was
absent for rabbit antiserum to HPV16 wild-type L1-VLP as
expected.
Antisera to RG1-VLP neutralize distantly related mucosal HPV
types in vitro
The spectrum of cross-neutralization induced by RG1-VLP
vaccination was further explored by analyzing rabbit antisera
(n¼ 10) in neutralization assays for a large panel of genus-a
HPV using additional PsV types (Table 1). Similar to findings
reported previously for rabbits 1/2 (*), the additional eight
rabbits’ immune sera contained high-titer neutralizing
antibodies against HPV16 (titers of 10,000–100,000).
Broad-spectrum cross-neutralization was found for species
a9 HPV31, 52, 58, 33, 35 (in 2, 5, 9, 6, and 9 out of 10
sera), a7 HPV18, 45, 39, 59, 68, 70 (9, 6, 5, 1, 2, 7/10), a5
HPV51, 26, 69 (3, 10, 2/10), a11 HPV73 and 34 (10 and 8/10)
(titers from 25 to 10,000), but not for a6 HPV 56, 53, and 66.
Cross-neutralization beyond mucosal HR types was analyzed
for the most potent sera nos. 1/2 (Table 2). Apart from LR
HPV6/11, a1 HPV32 (causing Heck’s disease) was neutralized
(titers of 50/100), whereas HPV44 (a10) sporadically found in
genital warts was not neutralized. To narrow the gap between
PsV-based in vitro assays and natural HPV infection,
RG1-VLP-induced neutralizing antibodies were also detected
using infectious native virions (Handisurya et al., 2007). As
shown in Figure 1a, HaCaT cells infected with HPV26 virions
(lane 2) revealed a specific band corresponding to spliced viral
mRNA in nested reverse transcriptase–PCR, in contrast to
uninfected control cells (lane 1). Preincubation of virions with
RG1-VLP antiserum (1:400) completely abolished mRNA
detection, indicating viral neutralization (lane 4), whereas
preimmune serum (lane 3), mAb RG1 (Gambhira et al.,
2007b) (lane 5), or serum from a Gardasil-vaccinated
individual (lane 6) had no effect. RG1-VLP antiserum also
cross-neutralized LR HPV40 (Figure 1b; lanes 5 and 6) and
HPV6 virions (see Supplementary Material online) at dilutions
of 1:100–400. Taken together, the in vitro cross-neutralization
spectrum of RG1-VLP vaccination includes almost all HR
HPVs causing CxCas, as well as LR mucosal types in PsV and
native virion–based assays.
Antisera to RG1-VLP cross-neutralize prevalent common
cutaneous and HR b HPVs
In immunocompetent individuals with palmoplantar and
plane warts, the most frequently detected types are genus a
HPV2/27/57 (Rubben et al., 1997), g HPV4, m HPV1, and a
HPV3/10. Genus b HPV5/8 have been first identified in
patients suffering from Epidermodysplasia verruciformis,
whereas a possible role of b papillomavirus in non-mela-
noma skin cancer pathogenesis is still controversial. Thus,
rabbit antisera nos. 1/2 were screened for cross-neutralization
against available cutaneous HPVs in pseudovirion-based
neutralization assay (PBNA; Table 2), showing previously
reported cross-neutralization of HPV5(*), and additionally of
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HPV3 (a2) and HPV76 (b4) (titers of 1,000/100), but not of
HPV4 (g1) or HPV38 (b2). Furthermore, antisera nos. 1 and 2
cross-neutralized native virions of HPV2 with titers of 800 and
1,600 (Figure 1c, lanes 5 and 11), and HPV27 at dilution
1:400 (Supplementary Material online). Interestingly, antiserum
to HPV2 L1-VLP neutralized HPV27, as did antiserum to
HPV27 L1-VLP (1:400), indicating that closely related genotypes
HPV2 and HPV27 (a4) may represent common serotypes
(antisera to HPV2/27 L1-VLP were a kind gift from L Gissmann,
DKFZ, Heidelberg, Germany). Neither HPV1 nor HPV4 virions
(Supplementary Material online) were cross-neutralized by
RG1-VLP antiserum. Sera of 7/8 prepubertal girls were neutra-
lizing against highly prevalent cutaneous HPV1 (Supplemen-
tary Material online), indicating robust seroconversion after
natural infection, whereas serum from a Gardasil-vaccinated
individual did not cross-neutralize cutaneous HPV4. Moreover,
the cross-neutralization spectrum of RG1-VLP vaccine even
extends to bovine papillomavirus type 1 in PBNA (Table 2).
RG1-VLP vaccination induces cellular immune responses
The enzyme-linked immunospot analysis of splenocytes from
mice vaccinated with RG1-VLP or similarly HPV16 L1-VLP
showed IFN-g-producing cells when stimulated with a
previously described HPV16 L1 cytotoxic T lymphocyte
epitope (Supplementary Material online), indicating the
induction of a strong cellular immune response (Ohlschlager
et al., 2003). In contrast, stimulation of cells with the RG1
peptide did not result in significant IFN-g production.
RG1-VLP antisera efficiently protect mice against experimental
vaginal challenge with mucosal HPV in vivo
Given the broad spectrum of HR HPVs cross-neutralized
in vitro, vaccine efficacy in vivo was determined using an
experimental mouse model (adapted from Roberts et al.,
2007). As expected, passive transfer of RG1-VLP antiserum
reduced vaginal infection in mice challenged with HPV16 PsV
to background levels, similar to HPV16 L1 VLP antiserum
(Figure 2a). Importantly, mice were also cross-protected from
infection with phylogenetically divergent types HPV31/33/35/
52/58 (a9), HPV18/45/39/59/68 (a7), HPV34/73 (a11),
HPV53/56/66 (a6), and HPV26/51 (a5), and LR HPV6 (a10)
and HPV43 (a8) (Figure 2b and c). Indicative, yet statistically
unsignificant, results were obtained for LR HPV44 (a10).
The level of cross-protection by RG1-VLP antiserum was
Table 1. Cross-neutralization of mucosal HR HPV by RG1-VLP antisera in PBNA in vitro
Neutralizing titers against high-risk genital HPV pseudovirions
RG1-VLP plus alum-MPL (50lg); weeks 0, 4, 6, and 8 (NZW; n¼ 6) RG1-VLP plus alum-MPL (20lg); weeks 0, 3, and 6 (NZW; n¼ 4)
1 2 3 4 5 6 7 8 9 10
HPV16 100,000 * 100,000 * 100,000 100,000 10,000 10,000 10,000 10,000 10,000 10,000
HPV18 1,000* 1,000 * 100 100 1,000 100 100 100 100 o25
HPV45 1,000 * 100 * o25 50 1,000 o25 o25 50 100 o25
HPV31 10,000 * 1,000 * o25 o25 o25 o25 o25 o25 o25 o25
HPV52 100 * 50 * 50 o25 25 o25 o25 o25 25 o25
HPV58 1,000 * 1,000 * 100 100 100 25 50 100 1,000 o25
HPV33 100 100 50 25 100 o25 o25 o25 100 o25
HPV35 1,000 1,000 100 100 1,000 100 50 100 1,000 o25
HPV39 500 100 o25 25 100 o25 o25 o25 50 o25
HPV56 o25 o25 o25 o25 o25 o25 o25 o25 o25 o25
HPV59 25 o25 o25 o25 o25 o25 o25 o25 o25 o25
HPV68 1,000 100 o25 o25 o25 o25 o25 o25 o25 o25
HPV73 1,000 1,000 1,000 100 100 100 50 25 100 25
HPV51 25 o25 o25 o25 o25 o25 o25 50 o25 50
HPV26 100 100 100 100 100 50 25 1,000 100 100
HPV53 o25 o25 o25 o25 o25 o25 o25 o25 o25 o25
HPV69 o25 o25 o25 o25 100 o25 o25 o25 50 o25
HPV66 o25 o25 o25 o25 o25 o25 o25 o25 o25 o25
HPV70 100 50 o25 100 1,000 50 o25 50 100 o25
HPV34 1,000 1,000 100 100 1,000 50 o25 o25 100 25
Abbreviations: alum-MPL, aluminum hydroxide plus 3-O-desacyl-40-monophosphoryl lipid A; HPV, human papillomavirus; HR, high risk; NZW, New Zealand
White; PBNA, pseudovirion-based neutralization assay; VLP, virus-like particle.
Antisera of 10 NZW rabbits raised against RG1-VLP were analyzed for cross-neutralization of 20 mucosal HR HPV pseudovirions in duplicates using end point
serial dilutions of 1:25–1:100,000. Neutralization titers were determined as described earlier (Schellenbacher et al., 2009). Data previously published are
indicated by ‘‘*’’ (Schellenbacher et al., 2009). Boxed titers indicate sera also tested for cross-neutralization in vivo (Figure 2a–c).
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indistinguishable from that induced by type-specific antisera
to the homologous L1-VLP, respectively, except for HPV53/
43/44, for which protection was recognizably lower. In
contrast, HPV16 L1-VLP antiserum showed predominantly
type-restricted protection against homologous HPV16, with
significant cross-protection against very closely related
HPV31/33/35 and to a smaller extent against more divergent
HPV56/59/6. Detectable in vitro cross-neutralization titers
(X25) were always accompanied by cross-protection in vivo
(Tables 1 and 2). However, RG1-VLP antisera also conferred
complete (HPV56) or at least partial cross-protection (HPV53/66)
in vivo (Figure 2a and b), for which types cross-neutralization
was not detected in vitro, suggesting low sensitivity of current
assays. To further demonstrate vaccine efficacy irrespective of
subtle cross-neutralization titers in vitro, antisera nos. 6/10
were selected for in vivo assays. Antisera nos. 6/10 demon-
strated a narrow cross-neutralization spectrum in vitro for only
6/19 or 3/19 mucosal HR types (Table 1). Although neither of
the two sera cross-neutralized HPV31/45 in vitro, both
effectively cross-protected against infection with HPV31/45
in vivo (Figure 2c).
Induction of long-lasting B-cell memory and cross-protection
To examine long-term B-cell memory after RG1-VLP vaccina-
tion, rabbits 1/2 were housed for a further 10 months after the
fourth immunization and boosted at week 52 with 50mg of
RG1-VLP (Supplementary Material online). When compared
with sera drawn at week 10, cross-neutralization titers had
declined 1–2 logs (HPV18/31) or beneath the level of
detection (HPV45/52/58/6/5) in week 52. A similar 2-log
decline was observed for neutralizing antibodies against
HPV16, which are predominantly induced by the L1 scaffold
of RG1-VLP. Importantly, boosting with RG1-VLP raised
antibody titers to former levels or beyond. To determine
whether cross-protection in vivo is also long lasting, antiserum
drawn at week 52 was analyzed for cross-protection against
in vivo challenge with HPV58. Although neutralization of
HPV58 was no longer detectable in vitro at week 52,
cross-protection was still conferred in vivo (Figure 2d), yet to
a slightly lesser extent as compared with sera drawn at
week 10 (Figure 2b).
DISCUSSION
The search for second-generation HPV vaccines is driven by
the need to protect against the plurality of carcinogenic genital
HPV by safe and affordable formulations. Because licensed
vaccines do not target HR HPVs other than HPV16/18,
causing 30% of CxCas, cytological screening programs cannot
be superseded. This major limitation in particular affects
developing countries, which bear 485% of the global CxCa
burden. Moreover, precancerous cervical neoplasia with a
substantial disease prevalence and morbidity in younger
women is even more strongly associated with types other
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Figure 1. In vitro reverse transcriptase–PCR (RT–PCR) neutralization assays
using native cutaneous and mucosal high-risk (HR) and low-risk (LR) human
papillomavirus (HPV) virions. HaCaT cells were incubated with native virions
of (a) mucosal HR HPV26, (b) mucosal LR HPV40, and (c) cutaneous HPV2.
Infection was detected by amplification of spliced viral mRNA. Cells were
either mock treated (cells only) or infected with native virus (þ ) in the absence
of serum (no serum), or with virions preincubated with (pre)immune sera at
indicated dilutions. Neither mAb RG1 nor a human antiserum from a Gardasil-
immunized individual neutralized infection with HPV26.
Table 2. Cross-neutralization of mucosal LR and
cutaneous HPV by RG1-VLP antisera in vitro
Pseudovirions Neutralizing titer
1 2
Low-risk mucosal
HPV6 * 100 50
HPV11 * 100 o25
HPV32 50 100
HPV44 o25 o25
Genus b
HPV5 * 100 50
HPV38 o25 o25
Common cutaneous
HPV3 1,000 1,000
HPV4 o25 o25
HPV76 100 100
Nonhuman
BPV1 100 100
Abbreviations: BPV1, bovine papillomavirus type 1; HPV, human papillo-
mavirus; LR, low risk; VLP, virus-like particle.
Antisera of two rabbits (nos. 1 and 2) raised against RG1-VLP were tested
for cross-neutralization of 4 LR mucosal, 2 genus b cutaneous, 3 common
cutaneous HPVs, and nonhuman BPV1 as indicated. Neutralizing titers
were determined as described in Table 1.
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than HPV16/18 (Tjalma et al., 2012). To extend protection to
the most common oncogenic HPVs, a nonavalent L1-VLP
vaccine (comprising seven HR and two LR types) is in clinical
trials. Although such a highly multivalent L1 vaccine is
expected to significantly increase the breadth of coverage,
L2-based vaccines are attractive as single-antigen formulations
targeting even more mucosal and, additionally, nongenital
types. The spectrum of L2-mediated cross-neutralization by
chimeric RG1-VLP has been analyzed by a limited number of
in vitro assays, whereas the vaccine’s efficacy to confer
protection in mammals against infection with a broad range
of HPVs has not been substantiated so far. In a very extensive
comparison of HPV16 L1 VLP versus RG1-VLP (plus alum-
MPL adjuvant) provided herein, RG1-VLP vaccination (cross-)
protects with high efficacy in vivo against infection with 18
divergent HR types out of 4 different species (a5/7/9/11),
which cause more than 95% of CxCas worldwide, and also
partially protects against the remaining four types tested (de
Sanjose et al., 2010). Mice were protected from vaginal
challenge with large doses of mucosal PsV despite
considerable antiserum dilution (B1:50) into the mouse
circulation. Interestingly, undetectable cross-neutralization
in vitro did not stringently imply incomplete protection
in vivo. In line with the recently reported insufficient
sensitivity of current in vitro assays to detect anti-L2
antibodies, in vivo testing has become the gold standard in
detecting neutralizing HPV antibodies (Longet et al., 2011)
and documenting vaccine efficacy. The results imply that the
actual immunogenicity is substantially greater than that
reflected by the standard in vitro neutralization assay, and
suggest that this vaccine should have a significant impact not
only on reducing the risk of CxCa but also on the overall
incidence of genital HPV infection, thus providing a major
advantage to HPV-based screening programs when compared
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Figure 2. Cross-protection against vaginal challenge with mucosal high-risk (HR) and low-risk (LR) human papillomavirus (HPV) in vivo. (a–d) In vivo vaginal
challenge with mucosal HPV in mice, passively transferred with RG1-VLP antiserum. Female Balb/c mice were injected intraperitoneally (i.p.) with 20ml of rabbit
(A) preimmune serum; (B) RG1-VLP immune serum (serum no. 1) (a, b); serum no. 6, no. 10 (c); (C) HPV16 L1-VLP antiserum; or (D) L1 antiserum to the
respective homologous type. Mice were challenged with pseudovirion (PsV) of (a) HPV16; (b) the next 11 most prevalent HR types HPV18, 45, 31, 33, 52, 58, 35,
39, 51, 59, and 68, and less frequent (o1%) types in cervical cancer (CxCa) HPV56, 73, 26, 53, 66, 34; LR HPV6, 43, and 44; or (c) high-risk HPV31 and 45.
(d) An RG1-VLP rabbit antiserum (no. 1) drawn at week 52 (10 months following the third boost with in vitro titer of o25 to HPV58) was analyzed for cross-
protection against challenge with HPV58 (B no. 1, week 52). Antisera to (d, C) HPV16 L1-VLP and (d, D) HPV58 L1/L2 PsV drawn 2 weeks after the third boost
were used as controls. Luciferase activity in bioluminescence imaging (Y axis: average radiance; p/s/cm2/sr) is given with the respective background luminescence
(unvaccinated mice challenged with carboxymethylcellulose (CMC) only) subtracted from all data points. P-values comparing groups A and B are indicated by
*Pp0.05, **Pp0.01, and ***Pp0.005.
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with the current vaccines. Complementary in vitro assays were
used to more extensively characterize the spectrum of cross-
neutralization by RG1-VLP vaccination, which was not
predicted by L1-based classification of papillomaviruses, the
site of infection, or host species. In PBNA, variable (cross)-
neutralization by RG1-VLP antiserum was detected for 17
mucosal HR types, whereas cross-protection in vivo was intact
for the serum with least potency in vitro. Although technically
demanding and limited to those few types available from
productive lesions, neutralization assays using native virions
may reflect viral infection more authentically than PBNA
(McLaughlin-Drubin et al., 2004). Reassuringly, the RG1-
VLP antisera neutralized lesion-derived virions as well. The
RG1-VLP antisera also cross-neutralized LR types HPV6/11
(a10), HPV32 (a1), HPV40 (a8), and cutaneous HPV2/27 (a4),
HPV3 (a1), and HPV76 (b3), but not HPV1 (m), HPV4 (g), and
HPV38 (b). On comparing the RG1 motifs of all types cross-
neutralized, sequence homology to HPV16 RG1 was at least
60% (see Supplementary Material online). Whether this lower
threshold of homology necessary for inducing cross-neutrali-
zation holds out in more sensitive in vivo assays needs to be
demonstrated. Therefore, RG1-VLP vaccination is expected to
protect against a substantial proportion of benign papillomas,
including both sexually transmitted genital and nongenital
skin warts. The latter is not only of tremendous clinical
importance for the growing group of immunocompromised
patients (e.g., organ-transplant recipients, HIV patients), but
may have expanded relevance if these types contribute to the
genesis of nonmelanoma skin cancers. Because the incidence
of common skin warts peaks in early childhood, this would
provide a rationale for implementing the vaccine into
existing childhood programs. Various approaches to enhance
cross-neutralizing L2 antibodies have been presented over the
past years, including conjugation of L2 peptides to a T-helper
epitope and a Toll-like receptor 2 ligand (Alphs et al., 2008),
concatenated multimeric L2 peptide vaccination (Jagu et al.,
2009), or display on bacteriophage (Tumban et al., 2012),
adeno-associated virus (Nieto et al., 2012), or HPV L1-VLP
(Zamora et al., 2006; Slupetzky et al., 2007; Kondo et al.,
2008; Schellenbacher et al., 2009; Caldeira Jdo et al., 2010).
Favorably, RG1-VLP vaccination plus alum-MPL (as in
Cervarix) not only elicits robust antibody responses against
RG1 in ELISA but also retains high-level protection against the
most important HPV16. Therefore, RG1-VLP vaccination
should provide strong protection not just against CxCas but
also against the even higher percentage of noncervical cancers
attributable to HPV16. In contrast, in a comprehensive direct
comparison, HPV16 L1-VLP vaccination protected against
HPV16 and 31 and only to a lower extent against 35, 39,
56, and 6. Licensed vaccines provide long-term protection of
at least 8.5 years, and the antibody levels required are still
unknown. Importantly, sera drawn 12 months after RG1-VLP
vaccination completely protected mice against vaginal
challenge with HR HPV58 in vivo. RG1-VLP holds promise
as next-generation vaccine with broad efficacy against the vast
majority of relevant mucosal and additional cutaneous
HPVs, provides a rationale for childhood vaccination, and
adds economic advantage of a single antigen formulation
compared with multivalent L1-VLP formulations. As
post-licensure data confirm excellent safety profiles for HPV
L1-VLP vaccines, we infer that RG1-VLP vaccination may
prove similarly safe, offering the possibility to evaluate vaccine
immunogenicity in early-phase human trials.
MATERIALS AND METHODS
Chimeric RG1-VLP
Chimeric HPV16 L1–HPV16 L2 (aa 17–36) VLP (RG1-VLP) have been
generated (Schellenbacher et al., 2009) by the insertion of HPV16
L2 peptide aa 17–36 (RG1) (Gambhira et al., 2007b) into the
DE-surface loop of HPV16 L1 and expressed in insect cells
(Kirnbauer et al., 1992).
Immunization
NZW rabbits were immunized with 50mg of RG1-VLP
subcutaneously (weeks 0, 4, 6, and 8, n¼ 6; NZW nos. 1–6) or
20mg of RG1-VLP (weeks 0, 3, and 6, n¼ 4; NZW nos. 7–10)
(Charles River, Kisslegg, Germany) adjuvanted with alum-MPL (10:1)
(Sigma Aldrich, St Louis, MO). Sera were drawn at weeks 10
(nos. 1–6) or 8 (nos. 7–10). Long-term antibody responses were
determined for NZW nos. 1/2 kept at 10 months. Sera were drawn
before and 14 days after final boost (week 52) and were stored at
 20 1C. For type-specific L1 antisera, a single rabbit each was
immunized with 20mg PsV of HPV6/26/34/35/39/43/44/51/52/53/56/
58/59/66/68/69, or 70, respectively (weeks 0, 3, and 6), in complete/
incomplete Freund’s adjuvant.
Native virion–based neutralization assays (reverse transcriptase–
PCR)
Native virions HPV2/27/1/4 were extracted from plantar warts; HPV6
from genital warts; HPV26 from a highly differentiated carcinoma
(Handisurya et al., 2007); and HPV40 virions were provided by
Neil Christensen (Hershey, PA) (Jenkins et al., 2003). After
mechanical disruption of wart tissue by high-speed homogenizer
(Fastprep-24, MP Biomedicals, Eschwege, Germany) and centrifuga-
tion (14,000 r.p.m./4 1C/5 minutes), supernatants containing virions
were used for neutralization assays (Smith et al., 1995; Slupetzky
et al., 2007). In brief, 3 105 HaCaT keratinocytes were infected with
virions that were either untreated or preincubated with rabbit antisera
and incubated overnight. Cellular RNA was reverse transcribed, and
spliced viral E1^E4 mRNA was identified by 30-cycle nested PCR
(95 1C/1 minute, 60 1C/1 minute, and 72 1C/3 minutes; for primer pairs
see Supplementary Material online).
Murine vaginal challenge
The intravaginal PsV challenge model (Roberts et al., 2007) was
performed with slight modification (Karanam et al., 2010). Female
Balb/C mice (groups of 5 or 10) were pretreated with 3 mg of
progesterone subcutaneously medroxyprogesterone (Depocou,
Pfizer, Vienna, Austria), and on day 3 they were passively trans-
ferred with 20ml rabbit antiserum: RG1-VLP (pre)immune serum
(rabbits 1, 6, and 10), or sera to L1-VLP of HPV16/31/33/45/6, to
L1/L2-VLP of HPV18 (J Schiller, NIH, Bethesda, MD), to L1-DNA of
HPV59/73, or to L1/L2-PSV of HPV26/34/35/39/51/52/53/56/58/66/
68/69/ or 70, respectively. After 24 hours, vaginal microtrauma
was induced by cervical cytobrush, and mice were challenged with
luciferase-encoding PsV in 3% carboxymethylcellulose. After 3 days,
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20ml of luciferin (Caliper, Waltham, MA; 7.5 mg ml 1) was applied
into the vagina, and infection was analyzed by bioluminescence
imaging (IVIS 50, Caliper). Data are given with background signal
subtracted (mice challenged with carboxymethylcellulose).
Statistical methods
Statistical analysis was performed using Microsoft Excel (heterosce-
dastic two-tailed unpaired t-test to evaluate P-values).
Standard techniques such as ELISA, PBNA, and enzyme-linked
immunospot assays are described in Supplementary Material online.
Consent and approval
Human sera and tissue samples were collected after written informed
consent of the patient or the patient’s guardian in accordance with the
Ethics Committee of the Medical University Vienna (ECS 1327/2012).
The study was conducted according to the Declaration of Helsinki
Principles.
Animal welfare
Animal studies have been approved (BMWF-66.009/0173-1I/3b/
2011) and animal care was in accordance with the guidelines of
the Austrian Federal Ministry for Science and Research.
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